Evolution of white matter tract microstructure across the life span
The human brain undergoes dramatic structural change over the life span. In a large imaging cohort of 801 individuals aged 7–84 years, we applied quantitative relaxometry and diffusion microstructure imaging in combination with diffusion tractography to investigate tissue property dynamics across th...
Saved in:
Published in | Human brain mapping Vol. 40; no. 7; pp. 2252 - 2268 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.05.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The human brain undergoes dramatic structural change over the life span. In a large imaging cohort of 801 individuals aged 7–84 years, we applied quantitative relaxometry and diffusion microstructure imaging in combination with diffusion tractography to investigate tissue property dynamics across the human life span. Significant nonlinear aging effects were consistently observed across tracts and tissue measures. The age at which white matter (WM) fascicles attain peak maturation varies substantially across tissue measurements and tracts. These observations of heterochronicity and spatial heterogeneity of tract maturation highlight the importance of using multiple tissue measurements to investigate each region of the WM. Our data further provide additional quantitative evidence in support of the last‐in‐first‐out retrogenesis hypothesis of aging, demonstrating a strong correlational relationship between peak maturational timing and the extent of quadratic measurement differences across the life span for the most myelin sensitive measures. These findings present an important baseline from which to assess divergence from normative aging trends in developmental and degenerative disorders, and to further investigate the mechanisms connecting WM microstructure to cognition. |
---|---|
Bibliography: | Funding information Fondation Leenaards; Roger De Spoelberch and Partridge Foundations; Swiss National Science Foundation, Grant/Award Numbers: 32003B_159780, 33CS30‐148401, 33CS30‐139468, 33CSCO‐122661, 3200B0‐118308, 3200B0–105993; GlaxoSmithKline; European Union's Horizon 2020 Research and Innovation Program, Grant/Award Number: 720270 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Funding information Fondation Leenaards; Roger De Spoelberch and Partridge Foundations; Swiss National Science Foundation, Grant/Award Numbers: 32003B_159780, 33CS30‐148401, 33CS30‐139468, 33CSCO‐122661, 3200B0‐118308, 3200B0–105993; GlaxoSmithKline; European Union's Horizon 2020 Research and Innovation Program, Grant/Award Number: 720270 Antoine Lutti and Bogdan Draganski contributed equally to this study. |
ISSN: | 1065-9471 1097-0193 |
DOI: | 10.1002/hbm.24522 |